Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.

doi:10.3390/ijms25063304

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.

International journal of molecular sciences - 14 Mar 2024

Ros Javier, Vaghi Caterina, Baraibar Iosune, Saoudi González Nadia, Rodríguez-Castells Marta, García Ariadna, Alcaraz Adriana, Salva Francesc, Tabernero Josep, Elez Elena

Abstract excerpt

Kirsten rat sarcoma virus oncogene homolog (KRAS) is the most frequently mutated oncogene in human cancer. In colorectal cancer (CRC), KRAS mutations are present in more than 50% of cases, and the KRAS glycine-to-cysteine mutation at codon 12 (KRAS G12C) occurs in up to 4% of patients. This mutation is associated with short responses to standard chemotherapy and worse overall survival compared to non-G12C...

Topics

Humans
Cetuximab
Panitumumab
Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins p21(ras)
Tremor
Colorectal Neoplasms
Mutation
Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38542278
DOI: 10.3390/ijms25063304
PMCID: PMC10970443

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics